Epitope Mapping of SARS-CoV-2 Spike Antibodies in Vaccinated Kidney Transplant Recipients Reveals Poor Spike Coverage Compared to Healthy Controls-Reference-Cited by-同舟云学术

Epitope Mapping of SARS-CoV-2 Spike Antibodies in Vaccinated Kidney Transplant Recipients Reveals Poor Spike Coverage Compared to Healthy Controls

Published:2023-11-29 Issue: Volume: Page:
ISSN:0022-1899
Container-title:The Journal of Infectious Diseases
language:en
Short-container-title:

Author:

Karaba Andrew H¹,Morgenlander William R²,Johnston Trevor S¹,Hage Camille¹,Pekosz Andrew¹³^ORCID,Durand Christine M¹,Segev Dorry L⁴,Robien Mark A⁵,Heeger Peter S⁶,Larsen Christian P⁷,Blankson Joel N¹,Werbel William A¹,Larman H Benjamin²,Tobian Aaron A R⁸^ORCID

Affiliation:

1. Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine , Baltimore, Maryland , USA

2. Institute for Cell Engineering, Division of Immunology, Department of Pathology, Johns Hopkins University School of Medicine , Baltimore, Maryland , USA

3. W. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins University Bloomberg School of Public Health , Baltimore, Maryland , USA

4. Department of Surgery, New York University Grossman School of Medicine , New York, New York , USA

5. Transplantation Branch, Division of Allergy Immunology and Transplantation, National Institute of Allergy and Infectious Diseases , Rockville, Maryland , USA

6. Department of Medicine, Comprehensive Transplant Center, Cedars-Sinai Medical Center , Los Angeles California , USA

7. Department of Medicine, Emory University , Atlanta, Georgia , USA

8. Division of Transfusion Medicine, Department of Pathology, Johns Hopkins University School of Medicine , Baltimore, Maryland , USA

Abstract

Abstract Kidney transplant recipients (KTRs) develop decreased antibody titers to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination compared to healthy controls (HCs), but whether KTRs generate antibodies against key epitopes associated with neutralization is unknown. Plasma from 78 KTRs from a clinical trial of third doses of SARS-CoV-2 vaccines and 12 HCs underwent phage display immunoprecipitation and sequencing (PhIP-Seq) to map antibody responses against SARS-CoV-2. KTRs had lower antibody reactivity to SARS-CoV-2 than HCs, but KTRs and HCs recognized similar epitopes associated with neutralization. Thus, epitope gaps in antibody breadth of KTRs are unlikely responsible for decreased efficacy of SARS-CoV-2 vaccines in this immunosuppressed population. Clinical Trials Registration. NCT04969263.

Funder

National Institutes of Health

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Immunology and Allergy

Link

https://academic.oup.com/jid/advance-article-pdf/doi/10.1093/infdis/jiad534/54450191/jiad534.pdf

Reference15 articles.

1. Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients;Boyarsky;JAMA,2021

2. Insufficient response to mRNA SARS-CoV-2 vaccine and high incidence of severe COVID-19 in kidney transplant recipients during pandemic;Reischig;Am J Transplant,2021

3. Randomized trial of a third dose of mRNA-1273 vaccine in transplant recipients;Hall;N Engl J Med,2021

4. A third dose of SARS-CoV-2 vaccine increases neutralizing antibodies against variants of concern in solid organ transplant recipients;Karaba;Am J Transplant,2022

5. The receptor-binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients;Premkumar;Sci Immunol,2020